在菲律宾,对COVID-19疫苗ECV-19进行的第3阶段试验报告,POP生物技术的抗体水平优于COVISHIELD,副作用小于COVISHIELD。 POP Biotech's Phase 3 trial of its COVID-19 vaccine, ECV-19, in the Philippines reported superior antibody levels and fewer side effects than COVISHIELD.

位于纽约州巴法罗的POP Biotechnologies公司报告了其在菲律宾进行的COVID-19疫苗候选者EuCorVac-19 (ECV-19) 的第三阶段试验中取得的积极的临时结果. POP Biotechnologies, based in Buffalo, NY, reported positive interim results from a Phase 3 trial of its COVID-19 vaccine candidate, EuCorVac-19 (ECV-19), conducted in the Philippines. 该研究有2 600人参加,并表明ECV-19与COVISHIELDTM疫苗相比,具有相当高的中和性抗体水平和较少的轻度副作用。 The study involved 2,600 participants and showed that ECV-19 produced significantly higher neutralizing antibody levels and fewer mild side effects compared to the COVISHIELD™ vaccine. 疫苗利用专有技术提高功效,菲律宾正在进行登记工作。 The vaccine employs proprietary technology to enhance efficacy, and registration processes are underway in the Philippines.